Valneva SE | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
30,445.00
36,922.00
78,360.00
94,062.00
105,291.00
113,035
Cost of Goods Sold (COGS) incl. D&A
24,291.00
26,784.00
55,710.00
51,806.00
54,553.00
47,625
Gross Income
6,154.00
10,138.00
22,650.00
42,256.00
50,738.00
65,410
SG&A Expense
33,713.00
34,972.00
47,406.00
54,047.00
55,365.00
63,153
EBIT
27,842.00
25,165.00
24,938.00
8,106.00
4,840.00
2,125
Unusual Expense
142.00
4,047.00
-
34,109.00
3,661.00
29
Non Operating Income/Expense
5,380.00
7,442.00
20,164.00
816.00
928.00
3,744
Interest Expense
1,212.00
4,394.00
9,716.00
6,087.00
5,059.00
3,789
Pretax Income
23,625.00
25,938.00
11,394.00
48,828.00
12,560.00
2,229
Income Tax
348.00
334.00
224.00
356.00
1,078.00
87
Equity in Affiliates
-
-
8,999.00
-
-
1,122
Consolidated Net Income
23,973.00
26,272.00
20,617.00
49,184.00
11,482.00
3,264
Net Income
23,973.00
26,272.00
20,617.00
49,184.00
11,482.00
3,264
Net Income After Extraordinaries
23,836.00
26,272.00
20,617.00
49,184.00
11,482.00
3,264
Net Income Available to Common
24,110.00
26,272.00
20,617.00
49,184.00
11,482.00
3,264
EPS (Basic)
0.55
0.42
0.28
0.66
0.15
0.04
Basic Shares Outstanding
43,629.90
61,539.40
72,740.30
74,658.90
77,449.20
80,529.30
EPS (Diluted)
0.55
0.43
0.28
0.66
0.15
0.04
Diluted Shares Outstanding
43,629.90
61,539.40
72,740.30
74,658.90
77,449.20
81,600.20
EBITDA
18,786.00
12,806.00
13,496.00
3,163.00
6,301.00
8,953
Other Operating Expense
283.00
331.00
182.00
3,685.00
213.00
132
Non-Operating Interest Income
191.00
226.00
3,096.00
290.00
72.00
178

About Valneva SE

View Profile
Address
Campus Bio-Ouest 6
Saint-Herblain Lorraine 44800
France
Employees -
Website http://www.valneva.com
Updated 07/08/2019
Valneva SE is a biotech company which engages in the development, production, and marketing of vaccine and preventive medicine. It operates through the following segments: Commercialized Vaccines, Technologies and Services, and Vaccine Candidates. The Commercialized Vaccines segment includes currently marketed vaccines of the group such as JEV and DUKORAL.